好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Optical Coherence Tomography (OCT) as a Diagnostic Tool in Sarcoidosis-associated Optic Neuropathy
Autoimmune Neurology
P3 - Poster Session 3 (5:00 PM-6:00 PM)
2-006

To characterize how neurosarcoidosis (NS) affects the optic nerve (ON) using optical coherence tomography (OCT) and assess its diagnostic utility in NS patients with and without neuro-ophthalmic manifestations.

The ON is the second most commonly involved cranial nerve in NS, yet the role of OCT in this population remains largely unexplored.

In this cross-sectional study, people with NS and age, sex, and race-matched healthy controls (HC) underwent OCT. Clinical data and magnetic resonance imaging (MRI) data were retrospectively reviewed. Only OCT scans meeting recognized quality control criteria were included. Analyses used linear generalized estimating equations.

A total of 239 NS and 256 HC eyes were included: 32 with ocular sarcoidosis (OcS), 42 with known clinical and/or radiological sarcoidosis-associated optic neuropathy (SAON), 11 with both OcS and SAON, and 154 eyes with NS but no known ocular or ON involvement (NSNON). Four mechanisms of SAON were identified: leptomeningeal infiltration/compression (47%), optic neuritis (43%), perineuritis (23%), and secondary to elevated intracranial pressure (13%).SAON eyes had lower peri-papillary RNFL (pRNFL) and ganglion cell+inner plexiform layer (GCIPL) thicknesses, as compared to HC (-16.9 µm and -11.7 µm respectively, p < 0.001 for all) and relative to OcS eyes (-16.0 µm and -12.0 µm respectively, p < 0.001 for all). OcS eyes had increased GCIPL thicknesses compared to HC (3.18 µm; p=0.035). Retinal layer thicknesses did not differ between NSNON and HC (-1.52 µm; p=0.298 and -0.43 µm; p=0.609, respectively).Quadrantal analysis of SAON revealed lower pRNFL thickness in all quadrants except nasal,as compared to HC (p=0.140).

Neuroaxonal injury to the ON in NS can be quantified by OCT. OCT is valuable in the diagnostic assessment of neuro-ophthalmic manifestations of sarcoidosis. Our findings do not suggest the presence of subclinical optic neuropathy in NS, unlike some other neuroinflammatory disorders. Future work will analyze longitudinal retinal changes.

Authors/Disclosures
Ruth Andrea Salazar Camelo, MD (Johns Hopkins School of Medicine)
PRESENTER
Dr. Salazar Camelo has nothing to disclose.
Munther Queisi, MD Dr. Queisi has nothing to disclose.
Cesar Higgins Tejera, PhD Mr. Higgins Tejera has nothing to disclose.
Angeliki Filippatou, MD (Johns Hopkins University School of Medicine) Dr. Filippatou has nothing to disclose.
Anna Melina Daniela Eva Luna Bacchetti, MD Dr. Bacchetti has nothing to disclose.
Ting-Yi Lin, MD (Charité–Universitätsmedizin Berlin) Dr. Lin has nothing to disclose.
Brenna McCormack, MBBCh Dr. McCormack has nothing to disclose.
KARTIKA GULATI, MD Dr. GULATI has nothing to disclose.
Keenan W. Davis, PhD Dr. Davis has nothing to disclose.
Gabriel Otero-Duran Mr. Otero-Duran has nothing to disclose.
Kathryn Fitzgerald, PhD (Johns Hopkins University) Dr. Fitzgerald has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Setpoint Medical. The institution of Dr. Fitzgerald has received research support from NIH. The institution of Dr. Fitzgerald has received research support from National MS Society.
Elias S. Sotirchos, MD (Johns Hopkins University) Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Sotirchos has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Sotirchos has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Sotirchos has received research support from National Institutes of Health. The institution of Dr. Sotirchos has received research support from National Multiple Sclerosis Society. The institution of Dr. Sotirchos has received research support from Sumaira Foundation. The institution of Dr. Sotirchos has received research support from Genentech. The institution of Dr. Sotirchos has received research support from UCB. The institution of Dr. Sotirchos has received research support from Astoria Biologica. The institution of Dr. Sotirchos has received research support from Ad Scientiam. The institution of Dr. Sotirchos has received research support from Alexion. The institution of Dr. Sotirchos has received research support from Corevitas. Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving as a Ad Hoc Reviewer with National Institutes of Health.
Peter A. Calabresi, MD, FAAN (Johns Hopkins University) Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. An immediate family member of Dr. Calabresi has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MyMD. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Myelin Repair Foundation. The institution of Dr. Calabresi has received research support from Genentech. Dr. Calabresi has received publishing royalties from a publication relating to health care. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Grant reveiwer with Myelin Repair Foundation. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker for CME with NYAS. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Academic CME.
Shiv Saidha, MD (Johns Hopkins) Dr. Saidha has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Setpoint Medical. Dr. Saidha has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReWind Therapeutics. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Pharmaceuticals. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Saidha has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Multiple Sclerosis Journal ETC. Dr. Saidha has stock in June Brain. Dr. Saidha has stock in Lapix Therapeutics. The institution of Dr. Saidha has received research support from Biogen. The institution of Dr. Saidha has received research support from Genentech. The institution of Dr. Saidha has received research support from Novartis. The institution of Dr. Saidha has received research support from Lapix Therapeutics. The institution of Dr. Saidha has received research support from Novartis.
Carlos A. Pardo-Villamizar, MD (Johns Hopkins U, Med Dept of Neurology) The institution of Dr. Pardo-Villamizar has received research support from National Institutes of Health. The institution of Dr. Pardo-Villamizar has received research support from Bart McLean Fund for Neuroimmunology Research .